Sabinsa Corporation received the Thomas Alva Edison Patent Award for the year 2004. This annual award instituted by the Research & Development Council of New Jersey, honors the most important scientific breakthroughs and revolutionary product innovations originating in New Jersey. Awards are given in various industrial categories after careful consideration by the Council, which is constituted by leading professionals from industry and academia. Sabinsa's U.S. patent (No. 5,804,596) for ForsLean® was the entry that received this honor in the Consumer/Small Company category. The patent covers the method of preparing a forskohlin composition from Coleus forskohlii extract and the use of forskohlin for promoting lean body mass and treating mood disorders.
The award was presented at the Council's Annual Awards Dinner on November 11, 2004 ,
at the Liberty Science Center, New Jersey. The other winners of the 2004 awards include
multinational giants such as Celgene Corporation, Merck & Co., Inc., Schering-Plough Research Institute,
Wyeth, International Specialty Products, Engelhard Corporation and Exxon-Mobil Research & Engineering. Earlier,
Sabinsa Corporation was a finalist for the award in the Health & Medicine category in the year 1999 for the patent on BioPerine®.
This is the second award for ForsLean® in the innovation arena. The product earlier won the Best New Product award in 2001 at Nutracon. In the words of Dr. Muhammed Majeed, Founder & CEO: "We strongly believe in our ForsLean ingredient, the forskohlin composition supported by this patent, and its ability to safely and effectively help individuals increase their lean body mass and improve overall health. Sabinsa was founded on the premise of creating innovative products through state of the art research, and this award is a testament to the company's ongoing efforts in this area."
Sabinsa Wins Again: Federal Court Denies Creative Compounds Motion
Listen to a brief video on ForsLean®
View past and recent advertisements
Innovative Ingredients Paper Weight loss approach
Sabinsa calls to readers' attention that some of the products, protocols and uses of the products described here in are or may be subject to various restrictions or limitations because of patents, exclusive or nonexclusive licenses, confidentiality agreements and other intellectual property or equivalent rights. Readers are advised to make an early and thorough investigation and inquiry into any product, protocol or use in which they may be interested, to see if any such rights might be applicable. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.